Dr Reddys Laboratories (RDY) EPS (Weighted Average and Diluted) (2012 - 2023)

Dr Reddys Laboratories' EPS (Weighted Average and Diluted) history runs 12 years deep, the most recent figure standing at $157.32 for Q2 2023.

• In Q2 2023, EPS (Weighted Average and Diluted) rose 1.84% year-over-year to $157.32; the TTM figure through Jun 2023 stood at $157.32 (up 1.84% YoY), while the FY2026 annual figure was $0.55, down 30.38% from the prior year.
• EPS (Weighted Average and Diluted) was $157.32 for Q2 2023 at Dr Reddys Laboratories, down from $164.95 in the prior quarter.
• In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $263.72 in Q1 2020 to a low of $0.0 in Q3 2022.
• Historically, EPS (Weighted Average and Diluted) has averaged $148.27 across 5 years, with a median of $162.21 in 2021.
• The sharpest annual moves came in 2019 and 2022: EPS (Weighted Average and Diluted) jumped 7109.14% in 2019, then plunged 100.0% in 2022.
• A 5-year view of EPS (Weighted Average and Diluted) shows it stood at $164.1 in 2019, then increased by 1.17% to $166.01 in 2020, then fell by 5.62% to $156.69 in 2021, then sank by 98.71% to $2.03 in 2022, then surged by 7658.96% to $157.32 in 2023.
• The last three EPS (Weighted Average and Diluted) figures came in at $157.32 (Q2 2023), $164.95 (Q1 2023), and $2.03 (Q4 2022), per Business Quant data.